Creative Planning
ADCT icon

Creative Planning’s ADC Therapeutics ADCT Stock Holding History

Creative Planning’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$296K Sell
79,034
-34,213
-30% -$135K ﹤0.01% 3435
2025
Q4 		$400K Buy
113,247
+6,596
+6% +$26.8K ﹤0.01% 3029
2025
Q3 		$427K Buy
106,651
+70,652
+196% +$223K ﹤0.01% 2857
2025
Q2 		$96.5K Buy
+35,999
New +$75.7K ﹤0.01% 3437
2025
Q1 		– Sell
-475
Closed -$945 – 3460
2024
Q4 		$945 Buy
+475
New +$1.24K ﹤0.01% 3527

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Creative Planning's ADCT Position: Q1 2026 in Review

Creative Planning reduced its ADC Therapeutics (ADCT) stake by 30% in Q1 2026, selling an estimated $135K and leaving 79,034 shares worth $296K. The position accounts for ﹤0.01% of the portfolio, ranked #3435.

Creative Planning first reported a position in ADCT in Q4 2024 and has held it in 5 quarters since. The position peaked at $427K in Q3 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Creative Planning held 79,034 shares of ADC Therapeutics worth $296K as of Q1 2026.
  • Creative Planning sold 34,213 ADC Therapeutics shares in Q1 2026, an estimated $135K.
  • ADC Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #3435 holding.
  • Creative Planning first reported a position in ADC Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Creative Planning's ADC Therapeutics position peaked at $427K in Q3 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.